MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Inclusion Criteria

• Age >= 18
• Written and signed informed consent must be obtained
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
• Weight >= 35 kg
• Participants must have histologically or cytologically, confirmed pancreatic adenocarcinoma: Cohort A: Participants with previously untreated metastatic pancreatic adenocarcinoma (1L metastatic disease) not previously treated with systemic therapies Cohort B: Participants with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, oxaliplatin) 2L metastatic disease
• Participants must have at least 1 measurable lesion according to RECIST v1.1
• All Participants must consent to providing archival tumor specimens.

Exclusion Criteria

• Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.
• Prior receipt of any immune-related therapy
• Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
• Participants with a history of venous thrombosis within the past 3 months
• Participants with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 3 months prior to start of treatment
• Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
• Other invasive malignancy within 2 years
• Any history of leptomeningeal disease or cord compression
• Current or prior use of immunosuppressive medication within 14 days prior to the first dose.